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Summary 
Background Sepsis is a major contributor to neonatal mortality, particularly in low-income and middle-income 
countries (LMICs). WHO advocates ampicillin–gentamicin as first-line therapy for the management of neonatal 
sepsis. In the BARNARDS observational cohort study of neonatal sepsis and antimicrobial resistance in LMICs, 
common sepsis pathogens were characterised via whole genome sequencing (WGS) and antimicrobial resistance 
profiles. In this substudy of BARNARDS, we aimed to assess the use and efficacy of empirical antibiotic therapies 
commonly used in LMICs for neonatal sepsis.
Methods In BARNARDS, consenting mother–neonates aged 0–60 days dyads were enrolled on delivery or neonatal 
presentation with suspected sepsis at 12 BARNARDS clinical sites in Bangladesh, Ethiopia, India, Pakistan, 
Nigeria, Rwanda, and South Africa. Stillborn babies were excluded from the study. Blood samples were collected 
from neonates presenting with clinical signs of sepsis, and WGS and minimum inhibitory concentrations for 
antibiotic treatment were determined for bacterial isolates from culture-confirmed sepsis. Neonatal outcome data 
were collected following enrolment until 60 days of life. Antibiotic usage and neonatal outcome data were assessed. 
Survival analyses were adjusted to take into account potential clinical confounding variables related to the birth 
and pathogen. Additionally, resistance profiles, pharmacokinetic–pharmacodynamic probability of target 
attainment, and frequency of resistance (ie, resistance defined by in-vitro growth of isolates when challenged by 
antibiotics) were assessed.  Questionnaires on health structures and antibiotic costs evaluated accessibility and 
affordability.
Findings Between Nov 12, 2015, and Feb 1, 2018, 36 285 neonates were enrolled into the main BARNARDS study, of 
whom 9874 had clinically diagnosed sepsis and 5749 had available antibiotic data. The four most commonly prescribed 
antibiotic combinations given to 4451 neonates (77·42%) of 5749 were ampicillin–gentamicin, ceftazidime–amikacin, 
piperacillin–tazobactam–amikacin, and amoxicillin clavulanate–amikacin. This dataset assessed 476 prescriptions for 
442 neonates treated with one of these antibiotic combinations with WGS data (all BARNARDS countries were 
represented in this subset except India). Multiple pathogens were isolated, totalling 457 isolates. Reported mortality 
was lower for neonates treated with ceftazidime–amikacin than for neonates treated with ampicillin–gentamicin 
(hazard ratio [adjusted for clinical variables considered potential confounders to outcomes] 0·32, 95% CI 0·14–0·72; 
p=0·0060). Of 390 Gram-negative isolates, 379 (97·2%) were resistant to ampicillin and 274 (70·3%) were resistant to 
gentamicin. Susceptibility of Gram-negative isolates to at least one antibiotic in a treatment combination was noted in 
111 (28·5%) to ampicillin–gentamicin; 286 (73·3%) to amoxicillin clavulanate–amikacin; 301 (77·2%) to ceftazidime–
amikacin; and 312 (80·0%) to piperacillin–tazobactam–amikacin. A probability of target attainment of 80% or more 
was noted in 26 neonates (33·7% [SD 0·59]) of 78 with ampicillin–gentamicin; 15 (68·0% [3·84]) of 27 with amoxicillin 
clavulanate–amikacin; 93 (92·7% [0·24]) of 109 with ceftazidime–amikacin; and 70 (85·3% [0·47]) of 76 with 
piperacillin–tazobactam–amikacin. However, antibiotic and country effects could not be distinguished. Frequency of 
resistance was recorded most frequently with fosfomycin (in 78 isolates [68·4%] of 114), followed by colistin 
(55 isolates [57·3%] of 96), and gentamicin (62 isolates [53·0%] of 117). Sites in six of the seven countries (excluding 
South Africa) stated that the cost of antibiotics would influence treatment of neonatal sepsis.
Interpretation Our data raise questions about the empirical use of combined ampicillin–gentamicin for neonatal 
sepsis in LMICs because of its high resistance and high rates of frequency of resistance and low probability of target 
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Research in context
Evidence before this study
We searched the PubMed, Ovid MEDLINE, Scopus, 
The World Health Organization Library Database, Popline, and 
ScienceDirect databases for articles published between 
Jan 1, 2010, and Jan 1, 2021. Searches were limited to English-
language articles and reviews were excluded. We searched for 
the terms “neonatal sepsis” and “neonatal mortality” but not 
limited to low-income and middle-income countries (LMICs) 
and linked these descriptions to the following terms: “virulence 
factors”, which identified three articles, of which one was of 
relevance and cited in our Article; “bacterial pathogenicity”, 
which identified 97 articles, none of which covered bacterial 
sepsis linked to Escherichia coli, Klebsiella pneumoniae, or 
Staphylococcus aureus; “target attainment”, which identified 
128 articles, none of which described the complete drug 
combinations analysed in our Article; and “economics”, which 
identified 97 references, eight that were of interest and one of 
which is cited in our Article. Furthermore, no relevant articles 
were found when we searched “LMICs” with “average income” 
and “antibiotic costs”. Despite the global interest in neonatal 
sepsis and mortality, we found no designed or undertaken 
prospective studies that combined microbiology, antibiotic 
kinetics, and health economics in a holistic manner to further 
understand the antibiotic treatment of neonatal sepsis and 
mortality.
Added value of this study
This study assessed empirical antibiotic treatment in neonates 
with biological sepsis from Bangladesh, India, Pakistan, 
Ethiopia, Nigeria, Rwanda, and South Africa. Data showed 
deviation from ampicillin plus gentamicin in multiple sites. 
This might be due to an absence of efficacy caused by high 
levels of resistance and low probability of target attainment 
found in this study in addition to high frequency of resistance 
rates for gentamicin. The combination of ceftazidime and 
amikacin had a higher probability of target attainment and 
lower prevalence of resistance than ampicillin–gentamicin and 
lower frequency of resistance rates for amikacin compared with 
gentamicin. Treatment with ceftazidime–amikacin was 
associated with reduced reported mortality compared with 
treatment with ampicillin–gentamicin. The reduction in 
reported mortality was significant for the subset analysed in 
this study (476 prescriptions), but was not significant when the 
effect of country was accounted for in the model, as therapies 
prescribed were disproportionately specified to a country, 
making country effects indistinguishable from antibiotic 
effects. Our health-cost survey showed that ampicillin and 
gentamicin were the most affordable antibiotics, followed by 
amikacin and ceftazidime. These antibiotics were available in all 
participating countries, except for amikacin which  was 
available in all countries excluding Ethiopia. Multiple antibiotics 
were not available in a range of countries and varied greatly in 
price. Participating sites in Bangladesh, India, Pakistan, 
Ethiopia, Nigeria, and Rwanda stated that the cost of more 
potent antibiotics is deferred to the patient. The average 
income of patients within the study was examined and, 
comparative to the cost of antibiotics when the cost was 
deferred to the patient, this will often make these antibiotics 
unaffordable. However, investigating the effect of cost on use 
of antibiotics was outside the remit of this study.
Implications of all the available evidence
Our study indicates that for neonatal sepsis the combination 
treatment of ampicillin–gentamicin needs to be reviewed for 
LMICs, and replaced with another combination, potentially 
ceftazidime–amikacin. As the frequency of resistance was high 
for fosfomycin, we suggest that this antibiotic is not considered 
for treatment of neonatal sepsis, singularly or in combination 
with other antibiotics, although further work is needed here. 
Data collected on antibiotic costs in LMICs are of concern 
because costs varied widely between antibiotics and between 
sites. The cost of an antibiotic inevitably affects therapy choice 
and invariably the outcome, particularly in Bangladesh, Nigeria, 
and Ethiopia. Selection of front-line antimicrobial regimes 
needs to account for the rise in antimicrobial resistance against 
broad-spectrum antibiotics, while balancing the need for 
effective therapy, cost, availability, dosing regimens, and 
potential toxicity.
Our data have immediate implications at every level of health 
care and suggest that WHO might need to revise their antibiotic 
guidelines for neonatal sepsis within LMICs, where antibiotic 
resistance to currently recommended treatments is extremely 
high. However, survival for neonates treated with ampicillin–
gentamicin was higher than expected despite the high resistance 
and low probability of target attainment, although we believe 
that this result was due to under-reported mortality. Further work 
needs to be carried out to understand this discrepancy.
Introduction 
An estimated 2·5 million neonates or infants in the first 
month of life die each year globally, with sub-Saharan 
Africa and Asia having the greatest mortality burden.1 
Neonatal sepsis often presents with varying clinical 
presentations and non-specific symptoms (such as 
Articles
www.thelancet.com/infection   Vol 21   December 2021 1679
lethargy and high temperature).2,3 In many low-income 
and middle-income countries (LMICs), where infant 
mortality is high, laboratory facilities to assess sepsis-
causing pathogens and associated antimicrobial resistance 
are often unavailable.4 Antibiotic treatment is therefore 
often empirical with therapeutic changes based on clinical 
response, which is difficult to monitor in LMIC settings.5
WHO recommends ampicillin in combination with 
gentamicin for the management of clinical neonatal 
sepsis;6 however, there are persistent concerns regarding 
antimicrobial resistance and therapeutic failures with 
this treatment.7 Additionally, suboptimal microbiological 
support in LMICs has led to the empirical use of 
broad-spectrum β-lactams, aminoglycosides, and even 
carbapenems.8 Antibiotic cost is not always covered by a 
hospital, state, or government, and might defer to 
patients, or only certain antibiotics might be covered, 
affecting neonatal outcomes when alternative treatments 
are unaffordable.
Access to effective antibiotics needs to be improved,9 
alongside preventing overuse of antibiotics. To reduce 
the use of certain antibiotics, the WHO Essential 
Medicines List for Children10 has classified antibiotics 
into three categories (Access, Watch, and Reserve). The 
Access group should account for more than 60% of 
antibiotic usage, providing adequate coverage for most 
common infections. The Watch group covers antibiotics 
with a broader spectrum and higher resistance potential. 
The Reserve group is for last-resort antibiotics targeting 
multidrug-resistant infections.10 Although use of Reserve 
antibiotics remains low, use of alternative antibiotic 
regimes have been reported in various countries for 
treatment of neonatal sepsis.9 This might represent an 
absence of antibiotic stewardship, or necessity because 
of ineffectiveness of antibiotics in the Access group.
WHO’s global action plan highlighted a need for 
antimicrobial resistance surveillance networks and 
centres to create and strengthen coordinated regional and 
global surveillance.11,12 In 2015, a Bill & Melinda Gates 
Foundation-funded study titled Burden of Antibiotic 
Resistance in Neonates from Developing Societies 
(BARNARDS) was established13 to assess the burden of 
neonatal sepsis and antimicrobial resistance in LMICs. 
The objectives of the main BARNARDS study included 
characterisation of common sepsis pathogens via whole 
genome sequencing (WGS), antimicrobial resistance 
profiles, assessment of carriage rates of antimicrobial 
resistance genes in the normal flora of mothers and 
neonates older than 7 days, and risk factors associated 
with neonatal sepsis. In this substudy of BARNARDS, we 
focused on the effectiveness of antibiotic therapies after 
determining a high prevalence of pathogens resistant to 
ampicillin and gentamicin.14 This Article describes the 
use of antibiotics in BARNARDS clinical sites, the 
effectiveness of recommended empirical treatment for 
neonatal sepsis, and examines potential alternative 
treatments. On the basis of resistance data collated in the 
main BARNARDS study, we hypothesised that neonates 
treated with ampicillin–gentamicin would have higher 
reported mortality than those treated with alternative 
combinations with a lower prevalence of resistance.
Methods 
Study design 
BARNARDS was an observational cohort study analysing 
sepsis rates in neonates and infants aged 0–60 days, both 
inborn (ie, born in the participating hospital) or those 
with clinical presentation of suspected sepsis (non-inborn 
cohort) in hospitals in LMICs between Nov 12, 2015, and 
Feb 2, 2018. Herein, the term neonate refers to 0–60 days 
of life. Countries with participating sites included 
Bangladesh, Ethiopia, India, Nigeria, Pakistan, Rwanda, 
and South Africa, with a total of 12 clinical sites.13 Ethical 
approval was obtained locally for each clinical site, 
granted via local ethics committees (appendix p 1). All 
mothers were enrolled alongside their neonates at clinical 
sites, either upon delivery (inborn cohort) or at clinical 
presentation of suspected sepsis (non-inborn cohort) and 
questionnaires were completed that included information 
on the birth of the neonate enrolled. All mothers provided 
informed consent (forms written in local languages; 
appendix p 1) and could withdraw from the study at any 
time.13 Stillborn babies were excluded from the study.
Blood samples were obtained from neonates presenting 
with clinical signs of sepsis according to phlebotomy 
checklists and microbiology protocols carried out at sites 
(appendix p 1). Bacterial isolates from positive blood 
cultures confirming sepsis were stored on charcoal 
swabs before being sent to Cardiff University (Cardiff, 
UK) under UN3373 transport regulations, where WGS 
was done and minimum inhibitory concentrations 
(MICs) were calculated. Neonates diagnosed with sepsis 
without a positive blood culture were categorised as 
clinically diagnosed, as were positive cultures that were 
deemed as contaminants. Antibiotic treatments were 
recorded on site. Neonatal outcome data were collected 
following enrolment until 60 days of life (appendix, p 1).15 
Neonates of parents who could not be contacted were 
considered as alive until their age at last observation.
BARNARDS neonates included in this study had 
available antibiotic information and pathogen WGS data. 
We collated antibiotic consumption data from all clinical 
sites and selected the four most common antibiotic 
combinations for analysis. The study size was based on 
the maximum number of cases treated with common 
antibiotic combinations found following retrospective 
clinical note review, with available WGS data. All neonates 
from this subset reported as deceased within 60 days of 
life were included in analyses.
Antibiotic susceptibility profiling 
Agar dilution was done to determine MICs for 14 and 
20 antibiotics against Gram-positive and Gram-negative 
sepsis isolates, respectively, validated against control 
See Online for appendix
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strains and analysed using European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) break-
points (version 9.0, 2019)16 (appendix pp 2–3). Coverage 
was determined as the proportion of isolates susceptible to 
at least one antibiotic in a combination. Isolates with MIC 
values determined as requiring increased exposure to an 
antibiotic were combined with resistant isolates. Additional 
analyses compared outcomes with coverage for neonates 
treated with an antibiotic combination prescribed with no 
treatment change following initial therapy. A scoping 
literature review was done to obtain a snapshot of 
global rates of resistance against ampicillin, gentamicin, 
ceftazidime, and amikacin (appendix p 3).
Pharmacokinetic and pharmacodynamic modelling 
Pharmacokinetic and pharmacodynamic analyses deter-
mined probability of target attainment values accounting 
for differences in dosing schedules, patient-specific 
characteristics, and MIC values of pathogens for neonates 
who received an antibiotic combination with no change in 
treatment. This was repeated for neonates who received 
additional antibiotic treatments to compare country-
specific differences in dosing schedules. The full analysis 
method is in the appendix (pp 4–6). Briefly, individual 
patient characteristics were derived using reference 
values17 for bodyweight, serum creatinine, and albumin, and 
applied for probability of target attainment simulations18 
using published population pharmacokinetic models for 
each antibiotic combination.11 Target attainment was 
met for a combination when at least one antibiotic 
reached their MIC-specific pharmacokinetic and pharma-
codynamic target value associated with efficacy. Simulated 
probability of target attainment values for each 
combination were compared with MIC distributions and 
a probability of target attainment of 80% or more after 
100 simulations and compared with observed survival. 
Additional probability of target attainment simulations 
were done for meropenem, fosfomycin, and colistin.
Frequency of resistance 
Frequency of resistance (ie, resistance defined by in-vitro 
growth of isolates when challenged by antibiotics) was 
assessed for antibiotics commonly used in the treatment 
of neonatal sepsis at BARNARDS sites and potential 
antibiotic alternatives with lower rates of resistance. 
Frequency of resistance isolates were based on different 
bacterial species, sequence types, outcomes, and resistance 
profiles from across clinical sites selected proportionally 
from the BARNARDS dataset but restrained to isolates 
recorded as sensitive during MICs separately for each 
antibiotic (appendix p 7). Frequency of resistance rates 
were calculated as the proportion of isolates needed to 
develop growth and colony forming units per mL.19
Virulence factors and pathogenicity indexing
Similar to criteria outlined for frequency of resistance 
isolate selection, virulence factors and pathogenicity 
indexing were also undertaken for a selection of isolates 
on the basis of varied bacterial species, sequence types, 
outcomes, and resistance profiles from a range of 
BARNARDS sites; however, clinical outcome was also 
considered (appendix p 7). Galleria mellonella models 
were used to determine bacterial pathogenicity indexes 
as previously described.20 In this model, bacterial 
isolates were grown in broth, centrifuged, washed, and 
resuspended in saline solution and injected at certain 
dilutions into Galleria larvae (10–⁷ to 10–⁸ dilutions for 
Enterobacteriaceae; 10–⁷ to 10–⁹ for Staphylococcus aureus). 
Ten larvae were used for each dilution per isolate in 
triplicate with controls used as previously outlined.20 
Galleria were kept at 37°C and mortality recorded at 24, 
48, and 72 h. Pathogenicity indexes were calculated from 
the proportion and time of larvae death from a bacterial 
dilution.
WGS and bioinformatics analyses were undertaken 
in the main BARNARDS study,14 (accession numbers: 
PRJEB33565 [Gram-negative isolates] and PRJEB40908 
[Gram-positive isolates]). Individual accession numbers 
are in the appendix (pp 8–10). Escherichia coli, Klebsiella 
pneumoniae, and S aureus isolates selected for 
pathogenicity indexing were analysed for the presence of 
virulence factors using Abricate (v 0.9.7) with the virulence 
factors database with a cutoff of 98% or more gene 
identity.21,22 A presence or absence matrix of virulence-
associated factors deposited in the database was created to 
generate a total virulence score (appendix p 7).22
Antibiotic costs and availability
To better understand neonatal sepsis treatment practices, 
questionnaires were sent and completed by the principal 
investigators at each BARNARDS clinical site. The 
questionnaire covered antibiotic availability, national 
public or private health partnerships, and antibiotic costs 
(ie, whether they were paid for by the hospital, state, 
government, or the patients). Data for standard dosing 
regimens were collected for clinical sites (appendix 
pp 11–12).
Statistical analysis 
Cox regression hazard ratios (HRs) were calculated in R 
v 4.0.2,23 using the Survival (v3.2.7),24 coxphf (v 1.13.1), and 
coxme (v 2.2.16)25 packages. Potential clinical confounding 
variables that affected these models were included in the 
analyses (detailed in the appendix p 14); HRs shown have 
been adjusted for these potential confounding variables. 
Proportional hazard assumptions were assessed via 
Schoenfeld residuals showing no patterns over time, unless 
otherwise stated. Survminer (version 0.4.8) and ggfortify 
(version 0.4.11) packages were used to create survival plots. 
Virulence factors and pathogenicity indexing R² correlations 
were done with Microsoft Excel. Normality and Mann-
Whitney U tests were run in IBM SPSS version 25 for 
associations between virulence factors or pathogenicity 
index and outcome, with sensitivity analyses undertaken 
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(appendix p 13). Frequency of resistance results were 
log-transformed with an added standard of 1 × 10–¹⁰ to 
incorporate zero values into violin plots, created in 
R (version 3.6.1) using the ggplot2 (version 3.3.2) package.23,26 
Pharmacokinetic–pharmacodynamic analysis was done 
in R (version 3.5.1)23 with the packages RxODE 
(version 0.9.1.1), ggplot 2 (version 3.3.0),26 and dplyr 
(version 0.8.5).
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
Between Nov 12, 2015, and Feb 1, 2018, 36 285 neonates 
were enrolled onto the main BARNARDS project, of 
whom 9874 had clinically diagnosed sepsis, 5749 had 
antibiotic data available (figure 1), and 2483 were 
confirmed with a positive blood culture. The four most 
common combinations of first-line antibiotics prescribed 
were given to 4451 neonates (77·4%) of 5749: 
Figure 1: Study profile
The diagram shows the process of isolate selection for inclusion in this study, as a substudy from the main BARNARDS project and subsets used for analyses. 
BARNARDS=Burden of Antibiotic Resistance in Neonates from Developing Societies. WGS=whole genome sequencing. MIC=minimum inhibitory concentration.
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Figure 2: Survival analysis for neonates treated with each antibiotic therapy
Analysis was done for 476 neonates through Cox regression hazard ratios, 
adjusted for clinical factors. Clinical variables considered included cohort, sex, 
type of pathogen (ie, Gram-negative vs Gram-positive); whether the neonate 
was delivered via caesarean section; and whether the neonate was premature 
(appendix, pp 14–15) and stratified for onset of sepsis (early-onset sepsis or 
late-onset sepsis) to meet proportional hazard assumptions. For the purpose of 
this survival curve, the following clinical variables were set: male sex, inborn 
cohort, early-onset sepsis, Gram-negative sepsis pathogen type, no caesarean 
section, and no premature neonates. 
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ampicillin–gentamicin administered by almost all sites 
across Africa and in Bangladesh; ceftazidime–amikacin 
used primarily by sites in Bangladesh with minor usage 
in Nigeria and Pakistan; piperacillin–tazobactam and 
amikacin (piperacillin–tazobactam–amikacin) used by 
sites in Pakistan and occasionally in South Africa and 
India; and amoxicillin clavulanate and amikacin 
(amoxicillin clavulanate–amikacin) used by sites in 
Nigeria (appendix p 14). We therefore assessed neonates 
treated with these four combinations in this study. 
Antibiotic prescription data was available for 1019 of 
2483 culturally confirmed sepsis cases. 300 of these 
isolates were not analysed further because of study 
constraints, lost viability, or they were deemed 
contaminants. Furthermore, 262 isolates were not related 
to treatment of the neonate with one of the top four 
antibiotic combinations. Therefore, this subset is based 
on 457 isolates from 442 neonates who were treated with 
one of the four common antibiotic combinations 
described above, for which WGS data were available. Of 
the isolates with WGS data, 12 had undetermined MIC 
results. However, these neonates were kept in the subset 
as they were valuable in contributing to other analyses. 
Multiple pathogens were isolated from 442 neonates, 
totalling 457 isolates (figure 1). Two of the above antibiotic 
combinations were prescribed as first-line and second-
line therapy to 34 neonates; both combinations were 
assessed, totalling 476 relevant prescriptions. Inborn and 
non-inborn neonates were included, with varied clinical 
presentations (appendix pp 14–15). From the 442 neonates 
included, 290 were treated with a single antibiotic 
combination only, with no change in therapy (figure 1).
BARNARDS countries were represented in this subset, 
except for India. However, antibiotic combinations were 
dominated by certain sites (appendix p 14). The 
proportion of neonates reported deceased in this subset 
was similar to those with confirmed sepsis overall from 
BARNARDS (X²[1] = 1·18, p=0·28).
Neonates treated with ceftazidime–amikacin had the 
lowest numerical reported mortality (16 [9·3%] of 172), 
followed by ampicillin–gentamicin (18 [16·2%] of 111), 
amoxicillin clavulanate–amikacin (19 [24·4%] of 78), and 
piperacillin–tazobactam–amikacin (32 [27·8%] of 115; 
appendix p 15). Neonates treated with ceftazidime–
amikacin had significantly reduced reported mortality 
compared with those treated with ampicillin–gentamicin 
(adjusted HR 0·32, 95% CI 0·14–0·72; p=0·0060; figure 2; 
appendix pp 16–18). No differences for reported mortality 
compared with ampicillin–gentamicin were found for 
neonates treated with amoxicillin clavulanate–amikacin 
(HR 1·19, 95% CI 0·60–2·24; p=0·62) or piperacillin–
tazobactam–amikacin (1·89, 0·88–4·06; p=0·10; figure 2). 
Significant results were negated in the mixed model with 
country incorporated as a random effect, although the data 
did not fit this model well because of the use of different 
antibiotics per country (appendix pp 16–18).
Analyses were repeated for 290 neonates treated with 
one antibiotic combination with no changes after initial 
treatment. No significant difference was found for this 
subset between ampicillin–gentamicin and ceftazidime–
amikacin (adjusted HR 0·51, 95% CI 0·16–1·69, p=0·27) 
or piperacillin–tazobactam–amikacin (3·02, 0·93–9·81, 
p=0·066) although higher mortality was associated 
with amoxicillin clavulanate–amikacin compared with 
ampicillin–gentamicin (5·56, 1·71–18·08; p=0·0044; 
Figure 3: Antibiotic resistance profiles according to EUCAST version 9.0 (2019)
(A) 390 Gram-negative isolates were tested against 20 antibiotics (minocycline is not shown as there is no defined 
breakpoint in EUCAST for Gram-negative species). (B) 55 Gram-positive isolates (33 for azithromycin) were tested 
against a panel of 14 antibiotics. Resistance profiles for 13 of 14 antibiotics tested against Gram-positive bacteria are 
shown (ampicillin is not shown as there is no defined breakpoint in EUCAST for Staphylococcus aureus against 
ampicillin,  because most Staphylococci are penicillinase producers making them resistant to ampicillin).16 Breakpoints 
for oxacillin and flucloxacillin are based on the assumption that isolates with MIC >2 mg/L are resistant because they 
carry mecA or mecC. These were also evaluated as meticillin-resistant S aureus (45·5% of isolates). MIC50 and MIC90 
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appendix pp 19–21). A high proportion of neonates 
treated with ampicillin–gentamicin who were not 
reported as deceased were followed up for fewer than 
10 days (55 [59·1%] of 93 compared with 37 [23·7%] of 














































































































































































































≥ 80% probability of target attainment Observed survival <80% 80–100% 100%
Ceftazidime–amikacin Piperacillin–tazobactam–amikacin
Ampicillin–gentamicin
Probability of target attainment
Amoxicillin–clavulanate–amikacin
Probability of target attainment
Figure 4: Probability of target 
attainment of commonly 
used antibiotic combination 
treatments
(A–D) Relationship between 
simulated probability of target 
attainment values and MIC 
values for four antibiotic 
combination therapies for 
290 neonates treated 
empirically with no following 
change in treatment. Vertical 
and horizontal lines represent 
ranges of MIC breakpoints 
according to EUCAST. Size of 
the bubbles indicates the 
frequency of isolates 
with associated MICs. 
(E) Comparison of simulated 
probability of target 
attainment values ≥80% 
(mean [1·96 SD]) and 
observed survival rate. 
(F) Simulated probability of 
target attainment values for 
the four combination 
therapies, compared with 
meropenem (10mg/kg every 
8 h), fosfomycin (200 mg/kg 
every 12 h), and colistin 
(5 mg/kg per day), based on 





Committee on Antimicrobial 
Susceptibility Testing.
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Gram-negative isolates were overwhelmingly resistant 
to ampicillin (379 [97·2%] of 390) and to gentamicin 
(274 [70·3%] of 390; figure 3; appendix p 22), with similar 
resistance results noted in sites across both African and 
south Asian continents (appendix pp 23–24). Amikacin 
had lower resistance (101 [25·9%] of 390) than other 
aminoglycosides, in keeping with global comparative 
data (appendix p 25). Few of the 390 Gram-negative 
isolates were resistant to fosfomycin (61 [15·6%]), 
imipenem (62 [15·9%]), and meropenem (56 [14·4%]). 
Regarding treatment combinations for the 390 Gram-
negative isolates, the lowest coverage was provided 
by ampicillin–gentamicin (111 [28·5%]), with higher 
coverage from amoxicillin clavulanate–amikacin 
(286 [73·3%]), ceftazidime–amikacin (301 77·2%]) and 
piperacillin–tazobactam–amikacin (312 [80·0%]). Gram-
positive isolates generally had reduced levels of resistance 
(figure 3; appendix pp 22, 24). Resistance rates varied 
between species, with high levels of resistance in 
K pneumoniae and Acinetobacter baumannii isolates 
(appendix pp 25–28).
MIC values were compared with reported outcomes for 
290 neonates with no change in therapy (figure 1). 
Pathogen susceptibility to at least one antibiotic or 
resistance to both antibiotics received by the neonate did 
not dictate outcome across treatment combinations tested 
(ampicillin–gentamicin: HR 1·28, 95% CI 0·25–6·60, 
p=0·77; ceftazidime–amikacin: 2·78, 0·35–22·24, p=0·34; 
amoxicillin clavulanate–amikacin: 0·37, 0·08–1·67, 
p=0·20; and piperacillin–tazobactam–amikacin 1·73, 
0·38–7·83, p=0·48). Unadjusted results provided due 
violations of proportional hazard assumptions in related 
adjusted models (appendix, pp 31–38).
Probability of target attainment values of 80% or more 
were predicted in 26 neonates (33·7% [SD 0·59]) of  78 with 
ampicillin–gentamicin; in 15 (68·0% [3·84]) of 27 with 
amoxicillin clavulanate–amikacin; 93 (92·7% [0·24]) of 
109 with ceftazidime–amikacin; and 70 (85·3% [0·47] of 
76 with piperacillin–tazobactam–amikacin. A reduction in 
probability of target attainment was most commonly 
predicted when there was resistance against both 
antibiotics of a combination treatment (figure 4). 
Probability of target attainment values aligned with 
observed survival rates (figure 4) for most treatments, 
except ampicillin–gentamicin, for which observed survival 
was higher than the probability of target attainment 
(33·7% vs 89·7%). Major differences in dosing schedules 
and resulting probability of target attainment values 
existed across study sites (appendix p 42). Sensitivity 
analyses showed that assumptions made regarding partly 
missing patient information did not significantly 
alter simulated probability of target attainment values 
(appendix p 43). In 290 neonates, mean probability of 
target attainment values of 80% or more adjusted to 
patient-specific MIC values were high for meropenem 
(290 [100%, SD 0]), fosfomycin (256 [89%, 0·16]) and 
colistin (290 [100%, 0]; figure 4). Reliable neonatal 
pharmacokinetic studies were available for meropenem; 
however, there were only a few fosfomycin and colistin 
pharmacokinetic studies, which moreover had a small 
sample size.27–29
Resistance occurred most frequently with fosfomycin 
(in 78 isolates [68·4%] of 114), followed by colistin 
(55 [57·3%] of 96), gentamicin (62 [53·0%] of 117), 
piperacillin–tazobactam (35 [34·3%] of 102), amoxicillin 
clavulanate (eight [33·3%] of 24), ceftazidime (17 [32·7%] 
of 52), ampicillin (one [16·7%] of six), amikacin 
(nine [7·7%] of 117) and meropenem (0 of 117; figure 5). 
Growth per mL was highest for gentamicin (4·44 × 10–³), 
with significantly higher growth per mL than all 
other antibiotics tested (ANOVA p<0·05; figure 5). 
Isolates for E coli had lower frequency of resistance 
than K pneumoniae isolates for most antibiotics tested 
(appendix p 44). Gram-negative species had varied 
frequencies of resistance to each antibiotic (appendix 
pp 45–47). Gram-positive isolates did not develop 
resistance against amikacin, although they did develop 
resistance against fosfomycin (one [5·3%] of 19), 
flucloxacillin (seven [36·8%] of 19) and gentamicin (four 
[21·1%] of 19; appendix p 47).
No correlations were found between pathogenicity 
indexing and virulence factors scores (R²=0·00–0·14); 
therefore both were analysed separately against 
outcomes. Lower virulence factor scores for E coli were 
associated with reported mortality (U=12·50, p=0·042) 
with no association between pathogenicity index and 
Figure 5: Frequency of resistance for Gram-negative isolates
Numbers included in the analysis and mean growth per mL were: amikacin n=117, 3·75 × 10–⁴; 
amoxicillin–clavulanate n=24, 2·50 × 10–³; ampicillin n=6, 6·67 × 10–⁷; ceftazidime n=52, 1·92 × 10–⁴; colistin n=96, 
4·17 × 10–⁴; fosfomycin n=114, 3·59 × 10–⁴; gentamicin n=117, 4·45 × 10–³; meropenem n=117, 0·00; and 
piperacillin–tazobactam n=102, 1·97 × 10–⁴. The numbers of isolates differed across antibiotics because of 
susceptibility patterns, with only sensitive bacteria suitable for frequency of resistance determination. 
Data are presented per mL and the frequency of resistance calculated from growth at a lower dilution on control 
plates free from antibiotics. Results have been log-transformed with a standard of 1 × 10–¹⁰ added to enable 
incorporation of zero values. This standard was chosen as the lowest rate of frequency of resistance 
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outcome (U=33·00, p=0·84). No associations between 
virulence factors or pathogenicity index and outcome 
were found for K pneumoniae (U=188·0, p=0·66; 
U=178·50, p=0·52, respectively) or S aureus (U=128·0, 
p=0·63; U=113·0, p=0·95, respectively; appendix p 48).
All sites except Nigeria offer ampicillin–gentamicin 
free of charge (table). Only sites in India and South Africa 
cover the costs of second-line or third-line antibiotics. For 
all other sites, access permitting, the patients bore the 
cost, which was as high as US$14·00 per day 
for meropenem; $8·00 per day for colistin; and 
$30·00 per day for tigecycline, often exceeding daily 
incomes. Costs varied greatly between sites, even within 
countries. Sites in six of the seven countries, except for 
South Africa, confirmed that cost of the antibiotic would 
influence treatment of neonatal sepsis (table).
Discussion 
High levels of antimicrobial resistance were found across 
both Africa and Asia, slightly higher in south Asia 
for Gram-negative isolates in keeping with previously 
published data,30,31 with higher resistance in Gram-positive 
isolates from Africa. Extremely high resistance was found 
against ampicillin of more than 97% in Gram-negative 
isolates, and Staphylococcus spp, which are regarded as 
intrinsically resistant to ampicillin;16 therefore, it can be 
argued that ampicillin is now redundant for treating 
neonatal sepsis in LMIC settings. Gentamicin with 
70·2% resistance in Gram-negative bacteria also did 
not have significant activity. Coverage for ampicillin–
gentamicin was 28·5% in Gram-negative isolates, further 
indicating the need for re-evaluation of the WHO 
recommendation for managing neonatal sepsis.
Empirical treatment for neonatal sepsis in LMICs is 
based on data from high-income countries (HICs) because 
of the sparsity of data from LMICs.7,12 Ampicillin is effective 
against pathogens common in HICs, such as group B 
streptococci and Listeria,7,30,31 although these species were 
not reported in this study, with reduced prevalence of these 
isolates in LMICs supported by previous studies.7,32,33 
Bangladesh Ethiopia India Nigeria Pakistan Rwanda South Africa
Average 
monthly salary
$228 (BK); $663 (BC) $142 $98 $81 (NK); $204 (NW); 
$274 (NN)
$316 (PP); $100 (PC) $250 (RK); $102 (RU) $274




tigecycline are paid for 
by the patient and not 
supplied by the hospital
Only ampicillin and 
gentamicin are 
available through the 
public system
Cost of antibiotics for 
neonates are borne by 
the West Bengal 
Government*
Cost of all drugs are 
mainly borne by 
patients; some financial 
support for government 
employees is given
Colistin, meropenem, 
and tigecycline are 
paid for by the 
patient
80% of the population 
have insurance, which 
covers payment for 
antibiotics; little data 
available on those who 
cannot afford insurance
Government 
covers the cost of 
all antibiotics
Is there private 
insurance and 
what role does 
it play?
Yes, but only for 
individuals with high 
incomes
Yes, but available to 
only a few people; 
poor people are not 
covered
Yes; widely used in India 
but not needed for the 
respondent’s hospital 
(Institute of Post 
Graduate Medical 
Education and Research)
Yes, but available to 
only a few people; 
most cannot afford this 
and are not covered
Yes; private insurance 
covers <1% of the 
population. Poor 
patients are covered 
by the government
Yes; of those with 
insurance, companies 
cover 85% of treatment 
costs
Yes; approximately 
20% of the country 
uses private health 
care
Local cost of antimicrobials per day (percentage of average daily wage based on 30 days per month)†
Ampicillin $0·35 (2–5%) $0·50 (11%) $0·15 (5%) $1·50 (17–56%) $0·50 (1–5%) $0·50 (6–15%) $0·60 (7%)
Gentamicin $0·20 (1–3%) $0·30 (6%) $0·20 (6%) $1·00 (11–38%) $0·60 (1–6%) $0·50 (6–15%) $0·40 (4%)
Ceftazidime $3·00 (1-40%) $3·50 (74%) $2·50 (76%) $3·50 (38–130%) $2·30 (6–22%) $2·00 (24–59%) $1·80 (20%)
Amikacin $0·50 (2–7%) Not available $1·00 (30%) $3·00 (33–111%) $0·50 (1–5%) $2·00 (24–59%) $0·40 (4%)
Amoxicillin–
clavulanate
Not available Not available $8·00 (242%) $10·00 (110–370%) Not available Not available Not available
Piperacillin–
tazobactam
$24·60 (111–309%) Not available $2·60 (79%) $20·00 (219–741%) $9·00 (22–86%) Not available $7·20 (79%)
Meropenem $10·00 (45–132%) $11·00 (234%) $6·40 (194%) $12·50 (137–463%) $6·50 (62–197%) $14·00 (169–412%) $3·50 (38%)
Colistin $8·00 (36–105%) Not available $9·00 (272%) Not available $8·00 (19–76%) Not available $6·00 (66%)




Yes Yes Yes Yes Yes Yes No
Site acronyms are provided where more than one clinical site in a country has participated in the BARNARDS study. Clinical sites included Kumudini Women’s Medical College (BK) and Chittagong Ma O Shishu 
Hospital (BC), Bangladesh; St Paul’s Hospital Millennium Medical College, Ethiopia; Institute of Post Graduate Medical Education and Research, Kolkata, India; Murtala Mohammad Specialist hospital, Kano (NK), 
Wuse District Hospital, Abuja (NW), and National Hospital Abuja (NN), Nigeria; Pakistan Institute of Medical Sciences (PP), and Community health centre, Bhara Kahu (PC), Pakistan; University Central Hospital of 
Kigali (RK) and Kabgayai Hospital (RU), Rwanda; and Tygerberg Academic Hospital, Cape Town, South Africa. Costs are given in US dollars for ease of comparison, with exchange rates calculated through www.
XE.com, March 2020. BARNARDS=Burden of Antibiotic Resistance in Neonates from Developing Societies. *India is a federal union split into 28 states and 8 union territories. Reliability for the information 
displayed in this table for India is limited to the state of West Bengal, where the clinical site in India is located. †Percentage cost of average daily wages are provided as averages per site within each country for 
two sites within a country. Percentages of average daily wage are presented as a single percentage for countries with a single site, or as a range for countries with two or more clinical sites, because of varied 
average wages and demographics between sites.
Table: Health-care matrix consisting of average salaries, costs of antibiotics, and coverage by governments across different BARNARDS study countries 
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Empirical therapies used by BARNARDS sites showed 
deviation from use of ampicillin–gentamicin, commonly 
sub stituting it with amoxicillin clavulanate–amikacin, 
piperacillin–tazobactam–amikacin, or ceftazidime–ami-
kacin, as supported by previous studies8 because of 
reduced clinical response to ampicillin–gentamicin.7
Amikacin, regularly used by sites, showed greater 
activity (74·0% susceptibility in Gram-negative isolates) 
than ampicillin and when paired with ceftazidime (which 
is on the WHO Watch list)10 provided 77·1% coverage 
against Gram-negative isolates. All BARNARDS sites 
except in Ethiopia had access to amikacin. Although 
more expensive (ranging from $0·40–3·00 per day 
compared with $0·15–1·50 per day for gentamicin), this 
was a small increase compared with alternative 
antibiotics. In all BARNARDS sites, ceftazidime was 
more expensive ($1·80–3·50 per day) than ampicillin 
($0·15–0·60 per day), which might affect the choice of 
empirical use. Although reported mortality was low 
among neonates treated with ampicillin–gentamicin, it 
was significantly lower with ceftazidime–amikacin. This 
was negated when country-specific analysis was applied. 
Ampicillin–gentamicin was prescribed across multiple 
sites, although other combinations were predominant 
at certain sites—eg, ceftazidime–amikacin was mainly 
prescribed in Bangladesh, amoxicillin clavulanate–
amikacin mainly in Nigeria, and piperacillin–tazobactam 
predominantly in Pakistan. Therefore, antibiotic effects 
could not be distinguished from country effects, which 
had different facilities and training and demands on 
staff, in addition to prevalence of resistance, bacterial 
strains, and patient characteristics. Some sites might be 
exposed to counterfeit antibiotics,34 which could also alter 
outcomes.
Probability of target attainment levels of 80% or more 
were low for ampicillin–gentamicin because of high 
levels of resistance, compared with the other treatment 
combinations of ceftazidime–amikacin, piperacillin–
tazobactam–amikacin, and amoxicillin clavulanate–
amikacin. Simulated probability of target attainment 
variation was small for all combinations, except for 
amoxicillin clavulanate–amikacin, for which significant 
inter-individual variation was observed. This study did not 
determine patient-specific antibiotic concentrations. 
However, variation in dosing schedules across sites and 
countries is an important factor to consider when 
comparing differences in treatment outcomes. The high 
reported survival rate relative to ampicillin–gentamicin 
probability of target attainment values could have arisen 
from under-reporting of mortality, as neonates not 
reported as deceased who were treated with ampicillin–
gentamicin were followed up for fewer than 10 days 
(59·1% of those treated with ampicillin–gentamicin vs 
23·7% of those treated with ceftazidime–amikacin). 
Follow-up is particularly difficult in LMIC settings, where 
mothers might live far away from clinical sites, or not 
have a contact number.
Amoxicillin clavulanate was not available in five of the 
seven countries in the study, and piperacillin–tazobactam 
was expensive (ranging from $2·60–24·60 per day). A 
high level of mortality was reported for neonates treated 
with piperacillin–tazobactam–amikacin (27·8%), despite 
high coverage for Gram-negative isolates. This might be 
due to confounding factors, as piperacillin–tazobactam–
amikacin is often used for nosocomial infections for 
which neonates were already admitted to hospital; 
however, the severity of neonatal sepsis was not recorded. 
This might again represent country effect, because 
most of the prescriptions for piperacillin–tazobactam–
amikacin were from sites in Pakistan. Outcomes might 
be negatively affected where patients bear the cost of 
antibiotic therapies and might not have been able to 
afford full courses of antibiotics.
Resistance to meropenem and fosfomycin (both on the 
WHO Watch list) and acquired resistance to colistin 
(on the WHO Reserve list) were low in addition to high 
probability of target attainment values simulated.35–37 
Frequency of resistance assessments, proposed by 
Sommer and colleagues19 to gauge robustness of antibiotic 
regimes, also suggested in our study that meropenem 
is a strong candidate as a single therapy.36 However, 
accessibility and costs currently preclude meropenem, 
fosfomycin, and colistin as treatment regimens for 
neonatal sepsis in LMICs. High frequency of resistance 
was seen against fosfomycin, supported by previous 
studies.37 However, growth per mL was similar to other 
antibiotics, potentially showing the presence of mutations 
that were unstable because of their fitness costs. However, 
da Campos and colleagues38 found that resistance had no 
or only minor effects on bacterial fitness in E coli strains; 
further work needs to be undertaken investigating the 
stability of fosfomycin resistance across bacterial species. 
Frequency of resistance for gentamicin was much higher 
than for amikacin, with significantly higher growth per 
mL, implying amikacin to be more robust, which might 
help to prevent selection for resistance over time with 
increased usage.
Associations were not found between pathogenicity or 
virulence factors and outcome, except for low virulence 
factor scores for E coli associated with higher reported 
mortality in neonates. It is possible that although an 
E coli bacterium might have numerous virulence factor 
genes, these might not be expressed or regulated. 
Discrepancies between outcome and microbiological 
data might be partly due to the numbers of neonates lost 
to follow-up. Antimicrobial resistance can affect bacterial 
virulence, but it is mechanism-dependent, which could 
possibly account for the absence of correlations.39
This substudy of a large international prospective 
study provides vital insights into antimicrobial usage 
and efficacy in LMICs, although it had several limitations. 
Outcomes were not always obtainable as neonates were 
sometimes lost to follow-up. This is an issue with 
observational studies, particularly within LMICs, where 
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mothers might live far from clinical sites or have no 
telephone for contacting. Neonatal bodyweight was not 
reported and was estimated from gestational and postnatal 
age for pharmacokinetic and pharmaco dynamic analysis.17 
There are no EUCAST break points for some antibiotic–
bacteria combinations; we extrapolated breakpoints from 
similarly related species. Frequency of resistance data 
were generated for single antibiotics only because it is 
problematic to choose concentrations for antibiotic 
combinations. Patient-specific dosing regimens were not 
available. Isolates were selected on the basis of antibiotic 
therapy given and available data, potentially biasing the 
inclusion of neonates from sites with information on 
antibiotic usage. Differences in antibiotics used per site 
led to indistinguishable country versus treatment effects 
for outcome. Clinical data did not state the severity of 
sepsis before treatment.
This study uniquely combines epidemiology, micro-
biology, pharmacokinetic and pharmacodynamic data, 
and health-cost matrices to understand immediate and 
future issues facing the effective treatment of neonatal 
sepsis in LMICs. Our combined MIC, frequency of 
resistance, and probability of target attainment data 
suggest that ampicillin is redundant in these settings 
and that the WHO-recommended combination of 
ampicillin–gentamicin for treatment of neonatal sepsis 
requires further scrutiny for LMICs. The results in this 
study suggest that ceftazidime–amikacin might be an 
effective potential alternative to ampicillin–gentamicin 
in LMICs. Further studies are urgently required to 
evaluate alternatives on neonatal outcomes.
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